Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Higher dose of schistosomiasis drug shows promise for toddlers

NCT ID NCT03640377

Disease control Sponsor: Rhode Island Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two doses (40 vs 80 mg/kg) of praziquantel in 354 children aged 1-4 with schistosomiasis in Uganda. The goal was to find the best dose to cure the infection and improve growth and anemia. Currently, praziquantel is not approved for children under 4, and this trial aims to fill that gap.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
praziquantel
What this could lead to
If successful, this could lead to better dosing guidelines for young children with schistosomiasis, improving cure rates and reducing disease burden.
What could go wrong
This is a Phase II trial with 354 children, so results are still preliminary. Higher doses may cause more side effects, and findings may not apply to all regions or parasite types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

354 people

The number who actually took part.

Started

Feb 2021

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 48 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * S. mansoni infection by urine CCA * Otherwise healthy as determined by history and physical examination conducted by the study physician at the second stage screening * Age 12-48 months inclusive * Parental consent to participate. Exclusion Criteria: * Parental inability to provide informed consent * Significant disease/illness as determined by history or physical exam. This includes a severe acute illness or chronic disease as defined by greater than 3 months duration and significantly impacting a child's daily activities. * Severe wasting as defined by WHZ \< -3, * Severe anemia (hemoglobin \< 7 g/dL) * Exposure to immuno-modulatory therapeutics.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schistosoma japonicum infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Schistosoma japonicum infectious disease Schistosoma mansoni infectious disease schistosomiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schistosoma japonicum infection Schistosomiasis Schistosomiasis mansoni

Contacts and locations

Locations

  • London School of Tropical Hygiene and Medicine

    London, United Kingdom

  • Medical Research Council

    Entebbe, 3FC6+Q3C,, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.